A living WHO guideline on drugs for covid-19

F Lamontagne; T Agoritsas; H MacDonald; YS Leo; J DIaz; A Agarwal; JA Appiah; Y Arabi; L Blumberg; CS Calfee; B Cao; M Cecconi; G Cooke; J Dunning; H Geduld; P Gee; H Manai; DS Hui; S Kanda; L Kawano-Dourado; YJ Kim; N Kissoon; A Kwizera; JH Laake; FR MacHado; N Qadir; R Sarin; Y Shen; L Zeng; R Brignardello-Petersen; L Lytvyn; R Siemieniuk; D Zeraatkar; J Bartoszko; L Ge; B Maguire; B Rochwerg; G Guyatt; PO Vandvik; P Natalia

Journal article

A living WHO guideline on drugs for covid-19

F Lamontagne, T Agoritsas, H MacDonald, YS Leo, J DIaz, A Agarwal, JA Appiah, Y Arabi, L Blumberg, CS Calfee, B Cao, M Cecconi, G Cooke, J Dunning, H Geduld, P Gee, H Manai, DS Hui, S Kanda, L Kawano-Dourado Show all

BMJ | Published : 2020

DOI: 10.1136/bmj.m3379

Abstract

AbstractClinical question What is the role of drug interventions in the treatment and prevention of covid-19? Recommendations The first version on this living guidance focuses on corticosteroids. It contains a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19. Corticosteroids are inexpensive and are on the World Health Organisation list of essential medicines. How this guideline was created This guideline reflects an innovative collaboration between the WHO and the MAGIC Evidence Ecosystem Foundation, driven by an urgent need for globa..

View full abstract